Arrowpoint Asset Management Has Decreased Alnylam Pharmaceuticals (ALNY) Stake by $4.02 Million as Market Valuation Rose; Mcdonald Capital Investors Holds Stake in Fastenal Co (FAST)

January 13, 2018 - By Hazel Jackson

Arrowpoint Asset Management Llc decreased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 6.39% based on its latest 2017Q3 regulatory filing with the SEC. Arrowpoint Asset Management Llc sold 34,400 shares as the company’s stock rose 48.45% with the market. The institutional investor held 503,889 shares of the health care company at the end of 2017Q3, valued at $59.20M, down from 538,289 at the end of the previous reported quarter. Arrowpoint Asset Management Llc who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be less bullish one the $12.80B market cap company. The stock increased 0.80% or $1.02 during the last trading session, reaching $129.07. About 796,481 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since January 13, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

Mcdonald Capital Investors Inc increased its stake in Fastenal Co (FAST) by 4.73% based on its latest 2017Q3 regulatory filing with the SEC. Mcdonald Capital Investors Inc bought 103,147 shares as the company’s stock declined 14.06% while stock markets rallied. The hedge fund held 2.29 million shares of the building materials company at the end of 2017Q3, valued at $104.17 million, up from 2.18 million at the end of the previous reported quarter. Mcdonald Capital Investors Inc who had been investing in Fastenal Co for a number of months, seems to be bullish on the $15.98 billion market cap company. The stock increased 0.91% or $0.5 during the last trading session, reaching $55.59. About 2.13M shares traded. Fastenal Company (NASDAQ:FAST) has declined 2.09% since January 13, 2017 and is downtrending. It has underperformed by 18.79% the S&P500.

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 89 analyst reports since August 7, 2015 according to SRatingsIntel. Chardan Capital Markets maintained the stock with “Buy” rating in Monday, June 12 report. The rating was maintained by BMO Capital Markets on Monday, June 26 with “Buy”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Needham on Monday, June 26. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Ladenburg Thalmann on Thursday, February 2. Jefferies maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, August 24 with “Buy” rating. The firm has “Outperform” rating by Leerink Swann given on Tuesday, May 3. The stock has “Buy” rating by Piper Jaffray on Sunday, January 7. Jefferies maintained the shares of ALNY in report on Thursday, October 6 with “Buy” rating. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. The firm has “Neutral” rating by Goldman Sachs given on Thursday, October 6.

Since September 20, 2017, it had 0 buys, and 3 insider sales for $23.18 million activity. Greene Barry E sold $10.66M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Monday, October 2.

Investors sentiment decreased to 0.92 in Q3 2017. Its down 0.60, from 1.52 in 2017Q2. It worsened, as 30 investors sold ALNY shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. 86.02 million shares or 0.72% more from 85.40 million shares in 2017Q2 were reported. Advisors Asset Incorporated holds 0.03% or 12,952 shares. Pub Employees Retirement Systems Of Ohio reported 32,880 shares or 0.02% of all its holdings. Qs Lc has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Blue Ridge Lc has invested 3.23% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Winfield Assocs holds 5 shares. Moreover, Millennium Management Ltd Liability Co has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Point72 Asset Management Ltd Partnership holds 85,000 shares or 0.04% of its portfolio. Boston Private Wealth Limited Liability, Massachusetts-based fund reported 2,105 shares. 34,700 are held by Serv Automobile Association. Peak6 Invests LP has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 8,275 were accumulated by Loring Wolcott & Coolidge Fiduciary Advsr Limited Liability Partnership Ma. M&T State Bank Corp owns 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 4,060 shares. Pacad Ltd invested in 2,400 shares. 3,485 were reported by World Asset. Td Asset Incorporated has 0.02% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 138,795 shares.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 14. They expect $-1.40 EPS, down 6.06% or $0.08 from last year’s $-1.32 per share. After $-1.34 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 4.48% negative EPS growth.

Arrowpoint Asset Management Llc, which manages about $5.56 billion and $8.80B US Long portfolio, upped its stake in Allegion Pub Ltd Co (NYSE:ALLE) by 252,995 shares to 728,815 shares, valued at $63.02 million in 2017Q3, according to the filing. It also increased its holding in H & E Equipment Services Inc (NASDAQ:HEES) by 97,613 shares in the quarter, for a total of 391,100 shares, and has risen its stake in Ss&C Technologies Hldgs Inc (NASDAQ:SSNC).

Among 17 analysts covering Fastenal (NASDAQ:FAST), 9 have Buy rating, 0 Sell and 8 Hold. Therefore 53% are positive. Fastenal had 56 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Fastenal Company (NASDAQ:FAST) has “Neutral” rating given on Thursday, August 27 by Susquehanna. The firm has “Neutral” rating by Robert W. Baird given on Monday, August 24. The company was upgraded on Thursday, January 12 by Avondale. The firm earned “Buy” rating on Tuesday, January 19 by Stifel Nicolaus. Macquarie Research initiated Fastenal Company (NASDAQ:FAST) rating on Friday, August 26. Macquarie Research has “Neutral” rating and $50 target. As per Tuesday, August 25, the company rating was maintained by William Blair. The firm earned “Outperform” rating on Wednesday, April 19 by Credit Suisse. The firm has “Hold” rating given on Monday, August 21 by Stifel Nicolaus. As per Tuesday, July 11, the company rating was maintained by BMO Capital Markets. The stock of Fastenal Company (NASDAQ:FAST) earned “Outperform” rating by William Blair on Monday, December 5.